{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:24:42Z","timestamp":1784125482194,"version":"3.55.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.biochi.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T03:12:11Z","timestamp":1592881931000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma"],"prefix":"10.1016","volume":"176","author":[{"given":"Anvar","family":"Soleimani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helale Kaboli","family":"Farshchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Mirzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvin","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Khorrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Mashayekhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3908-6828","authenticated-orcid":false,"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biochi.2020.06.001_bib1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/jclinpath-2013-201471","article-title":"Molecular biology of normal melanocytes and melanoma cells","volume":"66","author":"Bandarchi","year":"2013","journal-title":"J.\u00a0Clin. Pathol."},{"key":"10.1016\/j.biochi.2020.06.001_bib2","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3389\/fimmu.2017.01617","article-title":"Recent successes and future directions in immunotherapy of cutaneous melanoma","volume":"8","author":"Sadozai","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib3","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J. Clin."},{"issue":"36","key":"10.1016\/j.biochi.2020.06.001_bib4","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2009.08.005","article-title":"Treatment for metastatic malignant melanoma: old drugs and new strategies","volume":"74","author":"Mouawad","year":"2010","journal-title":"Crit. Rev. Oncol.-Hematol."},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ijc.1378","article-title":"Drug-resistance in human melanoma","volume":"93","author":"Helmbach","year":"2001","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.biochi.2020.06.001_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fonc.2018.00173","article-title":"Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance","volume":"8","author":"Ahmed","year":"2018","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s13402-019-00467-7","article-title":"Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications","volume":"43","author":"Rossari","year":"2020","journal-title":"Cell. Oncol."},{"issue":"4","key":"10.1016\/j.biochi.2020.06.001_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/1010428319837138","article-title":"The metabolic milieu in melanoma: role of immune suppression by CD73\/adenosine","volume":"42","author":"Passarelli","year":"2019","journal-title":"Tumour Biol."},{"key":"10.1016\/j.biochi.2020.06.001_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101304","article-title":"Targeting the adenosine pathway for cancer immunotherapy","volume":"42","author":"Hammami","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.biochi.2020.06.001_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.07.002","article-title":"Adenosine receptors as potential targets in melanoma","volume":"76","author":"Montinaro","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/eji.201041292","article-title":"Altered purinergic signaling in CD73-deficient mice inhibits tumor progression","volume":"41","author":"Yegutkin","year":"2011","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbamcr.2008.01.024","article-title":"Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade","volume":"1783","author":"Yegutkin","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1127496","article-title":"CD73-adenosine reduces immune responses and survival in ovarian cancer patients","volume":"5","author":"Gaudreau","year":"2016","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/1078-0432.CCR-15-1181","article-title":"CD73 expression is an independent prognostic factor in prostate cancer","volume":"22","author":"Leclerc","year":"2016","journal-title":"Clin. Canc. Res."},{"issue":"27","key":"10.1016\/j.biochi.2020.06.001_bib16","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1073\/pnas.1222251110","article-title":"CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer","volume":"110","author":"Loi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.cmr.0000215030.69823.11","article-title":"Expression of ecto-5\u2019-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma","volume":"16","author":"Sadej","year":"2006","journal-title":"Melanoma Res."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/jso.23056","article-title":"High expression of CD73 as a poor prognostic biomarker in human colorectal cancer","volume":"106","author":"Wu","year":"2012","journal-title":"J.\u00a0Surg. Oncol."},{"key":"10.1016\/j.biochi.2020.06.001_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/460654","article-title":"The roles of CD73 in cancer","volume":"2014","author":"Gao","year":"2014","journal-title":"BioMed Res. Int."},{"issue":"17","key":"10.1016\/j.biochi.2020.06.001_bib20","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1158\/0008-5472.CAN-17-0393","article-title":"Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis","volume":"77","author":"Young","year":"2017","journal-title":"Canc. Res."},{"issue":"4","key":"10.1016\/j.biochi.2020.06.001_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.18388\/abp.2012_2105","article-title":"Dual, enzymatic and non-enzymatic, function of ecto-5\u2019-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells","volume":"59","author":"Sadej","year":"2012","journal-title":"Acta Biochim. Pol."},{"issue":"8","key":"10.1016\/j.biochi.2020.06.001_bib22","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/bjc.2012.95","article-title":"NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity","volume":"106","author":"Wang","year":"2012","journal-title":"Br. J. Canc."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/1389557515666150219112630","article-title":"Structural and modeling studies on ecto-5\u2019-nucleotidase aiding in inhibitor design","volume":"15","author":"Furtmann","year":"2015","journal-title":"Mini Rev. Med. Chem."},{"issue":"12","key":"10.1016\/j.biochi.2020.06.001_bib24","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.str.2012.10.001","article-title":"Crystal structure of the human ecto-5\u2019-nucleotidase (CD73): insights into the regulation of purinergic signaling","volume":"20","author":"Knapp","year":"2012","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005943","article-title":"Identification of allosteric inhibitors of the ecto-5\u2019-nucleotidase (CD73) targeting the dimer interface","volume":"14","author":"Rahimova","year":"2018","journal-title":"PLoS Comput. Biol."},{"issue":"16","key":"10.1016\/j.biochi.2020.06.001_bib26","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cbic.201200426","article-title":"Crystal structure of a soluble form of human CD73 with ecto-5\u2019-nucleotidase activity","volume":"13","author":"Heuts","year":"2012","journal-title":"Chembiochem"},{"issue":"7","key":"10.1016\/j.biochi.2020.06.001_bib27","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/acs.jmedchem.9b00164","article-title":"Structure-activity relationship of purine and pyrimidine nucleotides as ecto-5\u2019-nucleotidase (CD73) inhibitors","volume":"62","author":"Junker","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"issue":"9","key":"10.1016\/j.biochi.2020.06.001_bib28","doi-asserted-by":"crossref","first-page":"14622","DOI":"10.1002\/jcp.28187","article-title":"CD73; a key ectonucleotidase in the development of breast cancer: recent advances and perspectives","volume":"234","author":"Soleimani","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00262-018-2290-1","article-title":"CD73 expression in normal and pathological human hepatobiliopancreatic tissues","volume":"68","author":"Sciarra","year":"2019","journal-title":"Canc. Immunol. Immunother. CII"},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41467-018-08123-8","article-title":"CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB\/CD137 therapy","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biochi.2020.06.001_bib31","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1002\/jcb.27091","article-title":"Role of adenosine signaling in the pathogenesis of head and neck cancer","volume":"119","author":"Khayami","year":"2018","journal-title":"J.\u00a0Cell. Biochem."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib32","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/jcp.27249","article-title":"Therapeutic potency of pharmacological adenosine receptors agonist\/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives","volume":"234","author":"Soleimani","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/biom5020775","article-title":"Extracellular adenosine generation in the regulation of pro-inflammatory responses and pathogen colonization","volume":"5","author":"Alam","year":"2015","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/imt.15.106","article-title":"CD73-adenosine: a next-generation target in immuno-oncology","volume":"8","author":"Allard","year":"2016","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.biochi.2020.06.001_bib35","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00109-018-01742-0","article-title":"The distinct role of CD73 in the progression of pancreatic cancer","volume":"97","author":"Zhou","year":"2019","journal-title":"J.\u00a0Mol. Med."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/BJ20111263","article-title":"The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism","volume":"441","author":"Garavaglia","year":"2012","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12885-017-3128-5","article-title":"CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity","volume":"17","author":"Gao","year":"2017","journal-title":"BMC Canc."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11302-012-9349-9","article-title":"Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?","volume":"9","author":"Kumar","year":"2013","journal-title":"Purinergic Signal."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2326-6066.CIR-14-0018","article-title":"Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity","volume":"3","author":"Bastid","year":"2015","journal-title":"Canc. Immunol. Res."},{"issue":"6","key":"10.1016\/j.biochi.2020.06.001_bib41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","article-title":"The equilibrative nucleoside transporter family, SLC29","volume":"447","author":"Baldwin","year":"2004","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"6","key":"10.1016\/j.biochi.2020.06.001_bib43","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2174\/138945012800564095","article-title":"Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders","volume":"13","author":"Antonioli","year":"2012","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pharmthera.2008.08.010","article-title":"Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications","volume":"120","author":"Antonioli","year":"2008","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jsps.2012.05.011","article-title":"Adenosine and its receptors as therapeutic targets: an overview","volume":"21","author":"Sachdeva","year":"2013","journal-title":"Saudi Pharmaceut. J."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib46","first-page":"527","article-title":"Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review)","volume":"32","author":"Hoskin","year":"2008","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib47","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/jcp.25873","article-title":"Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer","volume":"233","author":"Kazemi","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"12","key":"10.1016\/j.biochi.2020.06.001_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123837","article-title":"Targeting adenosine receptor signaling in cancer immunotherapy","volume":"19","author":"Sek","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biochi.2020.06.001_bib49","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc3613","article-title":"Immunity, inflammation and cancer: a leading role for adenosine","volume":"13","author":"Antonioli","year":"2013","journal-title":"Nat. Rev. Canc."},{"issue":"16","key":"10.1016\/j.biochi.2020.06.001_bib50","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-10-1544","article-title":"CD73: a novel target for cancer immunotherapy","volume":"70","author":"Zhang","year":"2010","journal-title":"Canc. Res."},{"issue":"17","key":"10.1016\/j.biochi.2020.06.001_bib51","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1158\/0008-5472.CAN-17-0395","article-title":"MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy","volume":"77","author":"Reinhardt","year":"2017","journal-title":"Canc. Res."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12967-017-1348-8","article-title":"Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab","volume":"15","author":"Morello","year":"2017","journal-title":"J.\u00a0Transl. Med."},{"issue":"42","key":"10.1016\/j.biochi.2020.06.001_bib53","doi-asserted-by":"crossref","first-page":"26659","DOI":"10.18632\/oncotarget.25426","article-title":"CD73 expression and clinical significance in human metastatic melanoma","volume":"9","author":"Monteiro","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13402-017-0359-z","article-title":"A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1\/2 phosphorylation","volume":"41","author":"Jafari","year":"2018","journal-title":"Cell. Oncol."},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13402-019-00456-w","article-title":"Recent advances in the clinical development of immune checkpoint blockade therapy","volume":"42","author":"Ghahremanloo","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.biochi.2020.06.001_bib56","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.22.012703.104731","article-title":"Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors","volume":"22","author":"Sitkovsky","year":"2004","journal-title":"Annu. Rev. Immunol."},{"issue":"6866","key":"10.1016\/j.biochi.2020.06.001_bib57","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/414916a","article-title":"Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage","volume":"414","author":"Ohta","year":"2001","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biochi.2020.06.001_bib58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Canc."},{"issue":"8","key":"10.1016\/j.biochi.2020.06.001_bib59","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/2159-8290.CD-14-0341","article-title":"Targeting cancer-derived adenosine: new therapeutic approaches","volume":"4","author":"Young","year":"2014","journal-title":"Canc. Discov."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","article-title":"Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses","volume":"30","author":"Young","year":"2016","journal-title":"Canc. Cell"},{"key":"10.1016\/j.biochi.2020.06.001_bib61","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bcp.2018.09.018","article-title":"The potential role of adenosine signaling in the pathogenesis of melanoma","volume":"156","author":"Bahreyni","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.biochi.2020.06.001_bib62","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00262-014-1553-8","article-title":"Extracellular adenosine metabolism in immune cells in melanoma","volume":"63","author":"Umansky","year":"2014","journal-title":"Canc. Immunol. Immunother. CII"},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/intimm\/dxt045","article-title":"Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible","volume":"26","author":"Ohta","year":"2014","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib64","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4049\/jimmunol.174.2.1073","article-title":"A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells","volume":"174","author":"Lappas","year":"2005","journal-title":"J.\u00a0Immunol."},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib65","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Canc. Immunol. Res."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib66","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2007-03-081646","article-title":"A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells","volume":"111","author":"Zarek","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib67","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4049\/jimmunol.173.2.932","article-title":"Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3\u2019,5\u2019-monophosphate and phosphatases","volume":"173","author":"Zhang","year":"2004","journal-title":"J.\u00a0Immunol."},{"issue":"9","key":"10.1016\/j.biochi.2020.06.001_bib68","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.4049\/jimmunol.0901247","article-title":"A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments","volume":"183","author":"Ohta","year":"2009","journal-title":"J.\u00a0Immunol."},{"issue":"12","key":"10.1016\/j.biochi.2020.06.001_bib69","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1158\/0008-5472.CAN-06-4249","article-title":"Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling","volume":"67","author":"Raskovalova","year":"2007","journal-title":"Canc. Res."},{"issue":"35","key":"10.1016\/j.biochi.2020.06.001_bib70","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib71","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.4049\/jimmunol.1200744","article-title":"Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma","volume":"189","author":"Forte","year":"2012","journal-title":"J.\u00a0Immunol."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib72","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22448","article-title":"The adenosinergic system in cancer: key therapeutic target","volume":"2","author":"Sorrentino","year":"2013","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/j.biochi.2020.06.001_bib73","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1172\/JCI45559","article-title":"CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice","volume":"121","author":"Wang","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"issue":"8","key":"10.1016\/j.biochi.2020.06.001_bib74","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-10-4246","article-title":"CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis","volume":"71","author":"Stagg","year":"2011","journal-title":"Canc. Res."},{"issue":"4","key":"10.1016\/j.biochi.2020.06.001_bib75","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood.V90.4.1600","article-title":"Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion","volume":"90","author":"Huang","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biochi.2020.06.001_bib76","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cellsig.2010.11.018","article-title":"Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells","volume":"23","author":"Mosenden","year":"2011","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib77","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/BJ20130064","article-title":"Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM\/ICER: a potential role for Epac","volume":"456","author":"Vang","year":"2013","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib78","first-page":"172","article-title":"Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model","volume":"4","author":"Iannone","year":"2014","journal-title":"Am. J. Canc. Res."},{"issue":"4","key":"10.1016\/j.biochi.2020.06.001_bib79","first-page":"1245","article-title":"A3 adenosine receptor agonist potentiates natural killer cell activity","volume":"23","author":"Harish","year":"2003","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.biochi.2020.06.001_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045401","article-title":"Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice","volume":"7","author":"Montinaro","year":"2012","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.biochi.2020.06.001_bib81","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1593\/neo.101628","article-title":"NK1.1 cells and CD8 T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model","volume":"13","author":"Morello","year":"2011","journal-title":"Neoplasia"},{"issue":"21","key":"10.1016\/j.biochi.2020.06.001_bib82","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1158\/0008-5472.CAN-14-1450","article-title":"Reducing CD73 expression by IL1beta-Programmed Th17 cells improves immunotherapeutic control of tumors","volume":"74","author":"Chatterjee","year":"2014","journal-title":"Canc. Res."},{"issue":"28","key":"10.1016\/j.biochi.2020.06.001_bib83","doi-asserted-by":"crossref","first-page":"25602","DOI":"10.18632\/oncotarget.4693","article-title":"A\u00a0non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation","volume":"6","author":"Morandi","year":"2015","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.biochi.2020.06.001_bib84","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-13-3583","article-title":"Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment","volume":"74","author":"Cekic","year":"2014","journal-title":"Canc. Res."},{"issue":"29","key":"10.1016\/j.biochi.2020.06.001_bib85","doi-asserted-by":"crossref","first-page":"20826","DOI":"10.18632\/oncotarget.24846","article-title":"Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity","volume":"9","author":"Tucci","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.biochi.2020.06.001_bib86","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.28456","article-title":"Anti-CD73 therapy impairs tumor angiogenesis","volume":"134","author":"Allard","year":"2014","journal-title":"Int. J. Canc."},{"issue":"6","key":"10.1016\/j.biochi.2020.06.001_bib87","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-011-1155-7","article-title":"Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor","volume":"61","author":"Waickman","year":"2012","journal-title":"Canc. Immunol. Immunother. CII"},{"issue":"10","key":"10.1016\/j.biochi.2020.06.001_bib88","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1593\/neo.09768","article-title":"A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin","volume":"11","author":"Merighi","year":"2009","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.biochi.2020.06.001_bib89","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/138920208785699580","article-title":"Cause and consequences of genetic and epigenetic alterations in human cancer","volume":"9","author":"Sadikovic","year":"2008","journal-title":"Curr. Genom."},{"key":"10.1016\/j.biochi.2020.06.001_bib90","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.39.1.295","article-title":"Cyclins and cell cycle checkpoints","volume":"39","author":"Johnson","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.biochi.2020.06.001_bib91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3","article-title":"Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor","volume":"186","author":"Ohana","year":"2001","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib92","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1006\/bbrc.1998.8714","article-title":"Adenosine receptor mediates motility in human melanoma cells","volume":"246","author":"Woodhouse","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib93","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/excr.2001.5327","article-title":"The A3 adenosine receptor as a new target for cancer therapy and chemoprotection","volume":"269","author":"Fishman","year":"2001","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.biochi.2020.06.001_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151420","article-title":"Specific activation of A3, A2A and A1 adenosine receptors in CD73-knockout mice affects B16F10 melanoma growth, neovascularization, angiogenesis and macrophage infiltration","volume":"11","author":"Koszalka","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.biochi.2020.06.001_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biocel.2015.10.003","article-title":"CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis","volume":"69","author":"Koszalka","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib96","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3892\/or.2013.2883","article-title":"Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in\u00a0vitro, but results in impaired angiogenesis and reduced melanoma growth in\u00a0vivo","volume":"31","author":"Koszalka","year":"2014","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.biochi.2020.06.001_bib97","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1002\/jcp.26743","article-title":"Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice","volume":"233","author":"Ghalamfarsa","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"5","key":"10.1016\/j.biochi.2020.06.001_bib98","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1084\/jem.20030891","article-title":"Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors","volume":"198","author":"Eltzschig","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"issue":"26","key":"10.1016\/j.biochi.2020.06.001_bib99","doi-asserted-by":"crossref","first-page":"10684","DOI":"10.1073\/pnas.0901326106","article-title":"Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells","volume":"106","author":"Ahmad","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"9","key":"10.1016\/j.biochi.2020.06.001_bib100","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1593\/neo.08478","article-title":"Host A(2B) adenosine receptors promote carcinoma growth","volume":"10","author":"Ryzhov","year":"2008","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib101","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1124\/mol.106.032920","article-title":"Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells","volume":"72","author":"Merighi","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib102","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/path.2045","article-title":"Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion","volume":"210","author":"Kaariainen","year":"2006","journal-title":"J.\u00a0Pathol."},{"issue":"36","key":"10.1016\/j.biochi.2020.06.001_bib103","doi-asserted-by":"crossref","first-page":"14711","DOI":"10.1073\/pnas.1308209110","article-title":"Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors","volume":"110","author":"Beavis","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"14","key":"10.1016\/j.biochi.2020.06.001_bib104","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-14-0957","article-title":"Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor","volume":"74","author":"Mittal","year":"2014","journal-title":"Canc. Res."},{"issue":"11","key":"10.1016\/j.biochi.2020.06.001_bib105","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.drudis.2017.06.005","article-title":"Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies","volume":"22","author":"Antonioli","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.biochi.2020.06.001_bib106","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1593\/neo.131748","article-title":"Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma","volume":"15","author":"Iannone","year":"2013","journal-title":"Neoplasia"},{"issue":"20","key":"10.1016\/j.biochi.2020.06.001_bib107","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","article-title":"Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs","volume":"19","author":"Allard","year":"2013","journal-title":"Clin. Canc. Res."},{"issue":"2","key":"10.1016\/j.biochi.2020.06.001_bib108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.neo.7900138","article-title":"Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists","volume":"3","author":"Bar-Yehuda","year":"2001","journal-title":"Neoplasia"},{"issue":"43","key":"10.1016\/j.biochi.2020.06.001_bib109","doi-asserted-by":"crossref","first-page":"42121","DOI":"10.1074\/jbc.M301243200","article-title":"A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition","volume":"278","author":"Madi","year":"2003","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908420301334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908420301334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:14:29Z","timestamp":1759540469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908420301334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":109,"alternative-id":["S0300908420301334"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2020.06.001","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma","name":"articletitle","label":"Article Title"},{"value":"Biochimie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biochi.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and Soci\u00e9t\u00e9 Fran\u00e7aise de Biochimie et Biologie Mol\u00e9culaire (SFBBM). All rights reserved.","name":"copyright","label":"Copyright"}]}}